Dr. Baas on Next Steps in the Treatment of Mesothelioma

Paul Baas, MD
Published: Thursday, Aug 18, 2016



Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.
SELECTED
LANGUAGE


Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x